Somatostatin Analogs Market with Potential Impact of Coronavirus (COVID19), SWOT Analysis, Risk Analysis, and Forecast

 Market Scope

Somatostatin analogs market 2020 can expect to capture a significant valuation of close to USD 8,640 Million by 2025, reveals MRFR (Market Research Future). MRFR also projects favorable prospects for the market at a CAGR of 6.8% between 2019 and 2025 (assessment period). We will provide COVID-19 impact analysis with the report, combined with an in-depth analysis following the coronavirus disease outbreak.

Request Sample Copy:

https://www.marketresearchfuture.com/sample_request/8633

Main Drivers and Deterrents

The American Association of Neurological Surgeons’ latest study reveals that close to 10-15 per million cases of Cushing’s syndrome emerge each year. The syndrome is commonly known to affect individuals in the age group of 20 to 50 years and is more prominent among the female population. Apart from this, the rising prevalence of NETs/neuroendocrine tumors has also been observed worldwide, in recent years. Estimations reveal that in the US alone, over 12,000 patients suffer from NETs annually; and roughly 170,000 patients live with the disease, as of 2019. In a nutshell, the surging burden of acromegaly, Neuroendocrine Tumors, Cushing syndrome, and similar other diseases has accelerated the growth of the Somatostatin analogs market.

Segmental Insight

Somatostatin analogs Market can be categorized with respect to type and application.

The Somatostatin analogs types available in the market include Lanreotide, Pasireotide and Octreotide. Octreotide is most likely to emerge as the top segment in the market as it notes the highest demand as a commercial vaccine. Pasireotide could be the fastest expanding segment in the years to come, on account of the surging knowledge with regard to the different treatment options among patients afflicted by Cushing’s syndrome, for which Pasireotide is the key treatment drug.

Somatostatin analogs find extensive applications in Cushing’s syndrome, acromegaly, neuroendocrine tumors (NETs), and more. Application of these drugs is most common in neuroendocrine tumor, which is expected to be the top segment during the conjectured period. However, the fastest growth will be witnessed by the acromegaly segment during the given period.

Regional Study

Europe, Americas, Middle East & Africa/MEA and Asia Pacific/APAC are the top markets for Somatostatin analogs across the world.

Canada and the US are the frontrunners in the worldwide healthcare industry, enabling the Americas to capture the leading position in the global market. High awareness level with regard to NETs and similar disorders, significant per capita income, and the rising entry of new vendors like Chiasma Inc. and Crinetics Pharmaceuticals have led to the introduction of a higher number of generic somatostatin analog drugs in the region. Acquisitions and mergers between reputed companies, substantial R&D spending, and the robust product pipeline also offer lucrative growth opportunities to the regional market.

Europe’s stand as the second highest gainer in the global market is the result of the growing investments by the renowned firms in the region, including Ipsen Pharma and Novartis AG. The regional market is also strongly influenced by the increased burden of NET and Acromegaly cases and the subsequent rise in the demand for effective treatment options. The thriving health care sector, substantial treatment and diagnosis rates of carcinoid tumors and various hormonal conditions, and the rising involvement of small firms in the development of new drugs can bolster the growth potential of the market in France, the UK and Germany.

Eminent Firms

Some of the highly eminent vendors profiled in the MRFR study are Ipsen Pharma (France), Peptron (South Korea), Teva Pharmaceuticals Inc. (Israel), Pfizer Inc. (US), Novartis AG (Switzerland), Fresenius Kabi (Germany), to mention a few.

The new industry entrants are Chiasma Inc. (US), Dauntless Pharmaceuticals (US), Sun Pharmaceutical Industries Ltd (India), Midatech Pharma plc (UK), Camurus AB (Sweden), Crinetics Pharmaceuticals (US), and more.

Browse Full Report @

https://www.marketresearchfuture.com/reports/somatostatin-analogs-market-8633

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

Comments

Post a Comment

Popular posts from this blog

North American Dental Equipment Market – Key Players, Size, Trends, Growth Opportunities, Analysis and Forecast

  North American Dental Equipment Market - Overview Over the last two hundred years, dentistry has made countless strides and also experienced a few setbacks globally. Though, the ultimate goal of the profession has always remained the same, which is to meet the treatment needs of the patient. Dental technology remains an important and valuable key to providing excellence in patient care. The role of today’s dental specialist has extended and evolved to being a gatekeeper of new product information, advisor on new restorative materials, imaging devices and radiology techniques, advocate of new technologies to improve consistency and accuracy, and educator for improved chair side techniques. Request Sample Copy: https://www.marketresearchfuture.com/sample_request/4625 At the same time, the industry endures to wrestle with new challenges redesigning the profession of dentistry. In a dental market where fewer percentage of educated and experienced dentists must meet the needs of an ever-g
Read more

Sports Medicine Market Global Analysis, Research, Review, Applications and Forecast

  Global Sports Medicine Market – Overview Sport medicines is a medical branch which deals with the treatment, prevention, and diagnosis of the injuries of the athletes. Sports medicines plays an important part in the sports. Many drivers and restrains affects the growth of the market during the forecast period. Increasing prevalence of sports injuries, increasing number of sports medicine associations, rising awareness alongside of the technological development are the major drivers for the market. From last couple of decades, more people are attracted towards different sports. Increasing awareness about fitness made people from different age groups to participate and join different sports clubs. This lead to more frequent sports injuries. Request Sample Copy: https://www.marketresearchfuture.com/sample_request/3503 According to the Centers for Disease Control and Prevention, on an average about 8.6 million sports and recreation related injuries episodes were reported in 2016. Moreove
Read more

Vocal Biomarkers Market Will Grow at CAGR During Forecast Period Global Evaluation by Trends, Proportions, Share, Swot, and Key Developments

  Market Highlights The vocal biomarkers market is chiefly driven by rise in cases of psychological, neurological and other diseases affecting speech such as depression, Attention Deficit and Disruptive Behavior Disorders, Parkinson's disease (PD), Alzheimer's disease, Huntington's disease, Respiratory and Cardiovascular Disorders, traumatic brain injury (TBI) etc. According to WHO estimates, around 350 million individuals were suffering from depression in 2016 while the Parkinson’s disease Foundation, estimated about 10 million individuals Parkinson’s patients globally in 2016. Thus, growing global disease prevalence will drive vocal biomarkers market size in the coming years. Another potential area of application is the use of voice biomarkers to detect disorders in employees and soldiers. For example, the U.S. Army entered collaboration with MIT researchers to develop voice biomarkers technology for traumatic brain injury. American Heart Association in collaboration with
Read more